New Drug Approval

 

 

New Drug Approval

 

1 Marzulene-S Combination Granules Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (launched in Japan at 1968, China at 1990, India at 2000 )
2 Azuloxa Granules 2.5% Gastric ulcer therapeutic agent (launched in Japan at 2001, launched in Korea 2004)
3 Marzulene Combination Tablets 1.0ES Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (Dosage form addition: launched in Japan at 2003)
4 Marzulene Combination Tablets 0.5ES Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (Dosage form addition: launched in Japan at 2008)
5 Marzulene Combination Tablets 0.375ES Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent (Dosage form addition: launched in Japan at 2009)
6 Azuloxa Tablets 15mg Gastric ulcer therapeutic agent (launched in Japan at 2011)
7 Suglat Tablets 25mg/50mg

Ipragliflozin(ASP1941)

Type2 Diabetes therapeutic agent/SGLT2 Inhibitor for Treatment (launched in Japan at 2014,Joint development with Astellas Pharma Inc.)
八重枝垂桜

 

R&D Pipeline(2017.5.22)

 

1 MK-0431J  (Ipraglifulozin / Sitagliptin) ①Development stage:Japan / Approval application
②Target:Type 2 diabetes ③Joint development:Astellas, MSD
2 S-556971 (KT6-971) ①Development stage:Japan / Phase Ⅱ, Europe / Phase I
②Target:Dyslipidemia ③Development:Kotobuki
3 ASP2215  (giliteritinib)
(“sakigake” fast-track drug)
①Development stage:the United States / Europe / Japan / Asia Phase Ⅲ
②Target:Acute myeloid leukemia ③Development:Astellas
①Development stage:the United States / Japan / Asia Phase Ⅰ
②Target:Non-small cell lung cancer ③Development:Astellas
4 Ipragliflozin ①Development stage:Phase Ⅲ ②Target:Type 1 diabetes
③Joint development:Astellas
5 ASP5878 ①Development stage:Phase Ⅰ ②Target disease:Cancer
③Development:Astellas
6 KT7-533:α-C-Galactosyl Ceramide (Phase I in preparation:Derivation ending)

 

ビデオ会議

 

中圧液体クロマトグラフィー

medium pressure liquid chromatography